EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
: Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) secondary to age‐related macular degeneration (AMD) in Japanese patients. Methods: This open‐label, multicentre, Phase I/II study enroled patients into Group A (single injection of ranibizumab nonrandomized doses of 0.3 or 0.5 mg followed by 11 monthly injections of the same dose) and Group B (12 monthly injections of ranibizumab randomized to 0.3 or 0.5 mg). The primary efficacy endpoint was the mean change from baseline in best‐corrected visual acuity (BCVA) score at Month 6. Safety was evaluated in all patients who received ranibizumab. Results: Of 88 patients enroled, 12 entered Group A (six per dose) and 76 entered Group B (0.3 mg: n = 35; 0.5 mg: n = 41). Mean change from baseline in BCVA was significantly increased for both doses (Group B) at Month 6 (0.3 mg: +8.1 letters, p = 0.0006; 0.5 mg: +9.0 letters, p < 0.0001) and Month 12 (0.3 mg: +9.5 letters, p = 0.0001; 0.5 mg: +10.5 letters, p < 0.0001). At Month 12, one patient (0.3 mg) and 0 patients (0.5 mg) lost ≥15 letters, while 37.1% (0.3 mg) and 31.7% (0.5 mg) of patients gained ≥15 letters. Ocular serious adverse events (SAEs) of the study eye were reported in 1 and 2 patients in the 0.3‐ and 0.5‐mg groups, respectively. Nonocular SAEs were experienced by 2 and 5 patients in the 0.3‐ and 0.5‐mg groups, respectively. No cases of endophthalmitis were reported. Conclusion: Ranibizumab was effective and well tolerated in Japanese patients with subfoveal CNV secondary to AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 4×
“In addition, the incidences of nonocular AEs suspected to be related to ranibizumab and AEs potentially related to systemic VEGF inhibition were also within the acceptable range and consistent with the earlier studies (Brown et al. 2006; Rosenfeld et al. 2006).”
BackgroundResultInfluentialPrevalence and Risk Factors for Age-Related Macular Degeneration in an Adult Japanese Population
Kawasaki, R., Wang, J. J., Ji, G.-J., Taylor, B., Oizumi, T., Daimon, M., Kato, T., Kawata, S., Kayama, T., Tano, Y., et al. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.11.015 · Cited by 138 · cited 1×
“However, another recent study (the Funagata study) of Japanese residents aged 35 years or older (n = 1758) between 2000 and 2002 suggested that although the prevalence of neovascular AMD was lower in Japanese women, it was similar to that seen in Caucasians for Japanese men (Kawasaki et al. 2008).”
ResultSelf-citation
Cited by
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Wong, C. W., Yanagi, Y., Lee, W.-K., Ogura, Y., Yeo, I., Wong, T. Y., & Cheung, C. M. G. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.002 · Cited by 346
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 271
Mitchell, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585394 · Cited by 102
Treatment Patterns and Health Care Costs for Age-Related Macular Degeneration in Japan
Kume, A., Ohshiro, T., Sakurada, Y., Kikushima, W., Yoneyama, S., & Kashiwagi, K. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.042 · Cited by 34
Metadata
- Authors
- Tano, Y., & Ohji, M.
- Venue
- Acta Ophthalmologica
- Publisher
- Wiley
- Published
- 2010-04-27
- Volume
- 88
- Issue
- 3
- Pages
- 309-316
- ISSN
- 0001-639X (ISSN-L)
- 1755-375X
- 1755-3768
- OpenAlex
- W1976685144
- Cited by
- 50
- References
- 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration. https://app.cochat.ai/papers/10.1111/j.1755-3768.2009.01843.x
- The paper
- Tano, Y., & Ohji, M. (2010). EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration. Acta Ophthalmologica. https://doi.org/10.1111/j.1755-3768.2009.01843.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.